These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37640233)

  • 1. Modeling the XBB strain of SARS-CoV-2: Competition between variants and impact of reinfection.
    Cheng Z; Lai Y; Jin K; Zhang M; Wang J
    J Theor Biol; 2023 Oct; 574():111611. PubMed ID: 37640233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
    Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.
    Halfmann PJ; Uraki R; Kuroda M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Kawaoka Y
    EBioMedicine; 2023 Jul; 93():104677. PubMed ID: 37352827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38258765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
    Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
    Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence and dissemination of SARS-CoV-2 XBB.1.5 in New York.
    Gámbaro F; Duerr R; Dimartino D; Marier C; Iturrate E; Mulligan MJ; Heguy A; Dellicour S
    Virus Evol; 2024; 10(1):veae035. PubMed ID: 38774310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.
    Ma KC; Shirk P; Lambrou AS; Hassell N; Zheng XY; Payne AB; Ali AR; Batra D; Caravas J; Chau R; Cook PW; Howard D; Kovacs NA; Lacek KA; Lee JS; MacCannell DR; Malapati L; Mathew S; Mittal N; Nagilla RR; Parikh R; Paul P; Rambo-Martin BL; Shepard SS; Sheth M; Wentworth DE; Winn A; Hall AJ; Silk BJ; Thornburg N; Kondor R; Scobie HM; Paden CR
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):651-656. PubMed ID: 37319011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
    DeGrasse DC; Black SD
    Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study.
    Selvavinayagam ST; Karishma SJ; Hemashree K; Yong YK; Suvaithenamudhan S; Rajeshkumar M; Aswathy B; Kalaivani V; Priyanka J; Kumaresan A; Kannan M; Gopalan N; Chandramathi S; Vignesh R; Murugesan A; Anshad AR; Ganesh B; Joseph N; Babu H; Govindaraj S; Larsson M; Kandasamy SL; Palani S; Singh K; Byrareddy SN; Velu V; Shankar EM; Raju S
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100272. PubMed ID: 38076717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Surveillance for SARS-CoV-2 Variants: Dominance of XBB Replacement - China, January-June 2023.
    Feng Y; Su Q; Li L; He X; Niu P; Guo X; Zhao X; Tang J; Jia Z; Wang J; Wu C; Xia B; Chen Z; Wu Y; Yang J; Chen S; Chen C; Wang S; Dong X
    China CDC Wkly; 2024 Apr; 6(15):324-331. PubMed ID: 38736991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2.
    Popovic ME
    Microbiol Res; 2023 May; 270():127337. PubMed ID: 36804126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2023 Sep; 29():e942244. PubMed ID: 37654205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.
    Popovic M
    Microb Risk Anal; 2023 Apr; 23():100250. PubMed ID: 36777740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.